

The life sciences leader's guide to today's top oncology trends

Learn about the biggest trends impacting oncology providers, how those trends are altering cancer care delivery, and how your customers are approaching competition in this changing landscape.

4 trends impacting the oncology market

01 Cancer care is moving out of the cancer center and into the home.

- Necessary delivery of at-home cancer care during the pandemic illustrated that home-based care programs can reduce costs, increase capacity, and address patient preferences and needs.
- In the last four years, cancer programs have continued to expand their telehealth, home-based care, and remote patient monitoring offerings. Today, 97% of cancer programs offer virtual visits to at least some of their patients, compared to only 52% in 2019.¹
- These factors have led to a shift: cancer programs now see home cancer care as a business opportunity, rather than a temporary measure to minimize viral exposure.

02 Traditional cancer service area is redefined beyond geography.

- Most cancer services can now be delivered at home, virtually, or in satellite sites of larger cancer programs. Thus, patients don't need to visit a cancer program's main center as frequently, and in some cases, they may never meet their oncologist in person. For example, the VA has created a national virtual oncology service, allowing their oncology specialists to treat cancer patients across the country through telehealth.
- While completely virtual care delivery is not the norm, consolidation among health systems and cancer practices means other providers now have the scale to build national tele-oncology programs like the VA's. These changes indicate that a cancer program's service area no longer needs to be exclusively tied to a specific geographic area.

The tech-enabled cancer patient journey



03 Non-traditional investors and stakeholders disrupt the oncology ecosystem.

- Stakeholders including health plans, employers, and solutions providers (such as digital health vendors) are investing in cancer care delivery and support services. For example:
 - Several companies have recently launched services to help plans and employers steer patients to certain low-cost or high-quality networks of providers.
 - Health plans, employers, and solutions providers alike are taking on a larger role in patient support, including providing care managers to help patients navigate their care journeys.
- These stakeholders are shifting from offering point solutions to offering comprehensive care platforms — expanding their influence across the care continuum.
- As new actors get involved in cancer care, care delivery will be increasingly controlled by an entire ecosystem of stakeholders, rather than just the provider.

Stakeholder involvement in cancer care delivery

	Diagnosis	Treatment decision	Active treatment	Care management	Support services	Survivorship	End-of-life care
Providers							
Employers							
Plans							
Solutions providers							

Relative scale of involvement

Large
 Medium
 Small
 Minimal

Understand cancer provider priorities

The widespread adoption of telehealth and home-based care has expanded the traditional service area, leading to national competition among cancer providers. To compete in this new environment, your customers are differentiating through strategies aligned with their specific archetypes. Consider these archetypes and their corresponding growth strategies when shaping how you work with them.

Organization type (Archetype)	Approaches to growth and competition	Priorities
Large health systems (Scaled innovators)	<ul style="list-style-type: none"> Opening new sites to expand care delivery footprints Pursuing National Cancer Institute (NCI) designation Bolstering clinical research programs and offering the latest clinical innovations 	<ul style="list-style-type: none"> Improve patient convenience Offer quicker access by increasing capacity Build brand awareness Improve quality Receive additional research funding Differentiate from competitors Highlight innovation to community
Cancer practices (Value drivers)	<ul style="list-style-type: none"> Aggregating into networks to obtain scale Investing in value-based care as a primary differentiator 	<ul style="list-style-type: none"> Centralize administrative and technology services Provide access to clinical research, integrated pharmacies, lab services, and a wide range of peer experts Appeal to health plans, employers, and at-risk primary care groups Increase flexibility to design patient-centered care models
NCI-designated cancer centers (Expert partners)	<ul style="list-style-type: none"> Building new cancer hospitals Expanding second opinion programs Affiliating with community cancer centers 	<ul style="list-style-type: none"> Differentiate through specialization Become top choice for sickest patients Attract new patients Diversify revenue streams Enhance reputation Grow referral network and expand brand presence Improve care coordination, patient outcomes, and resource sharing
Hospitals and small health systems (Local leaders)	<ul style="list-style-type: none"> Making reactive moves to stay afloat Enhancing patient support programs Launching new community programs 	<ul style="list-style-type: none"> Create adaptable programs that can weather the evolving market Improve quality Avoid volume loss to other programs Expand access and solidify loyalty in the local market

Strategies to guide your interactions with oncology providers

Life sciences companies can improve their partnership strategies and enable commercial growth by accounting for the trends impacting cancer providers today. Consider the opportunities below as you develop a plan for your approach to cancer providers.

01 Cancer care is moving out of the cancer center and into the home.

- **All life sciences:** Collaborate with oncology providers to create and test solutions to enable home cancer care delivery.
- **Pharma:** Expect more demand for oral chemotherapeutics and self-administered treatments that are safe for home use. Offer solutions for improving treatment adherence.
- **Medtech:** Communicate how your innovative medical devices and monitoring equipment can be used easily by patients or clinicians located far from the cancer center. Prepare for rising customer interest in platforms that enable telehealth, remote patient monitoring, e-consults, and real-time data sharing.

02 Traditional cancer service area is redefined beyond geography.

- **All life sciences:** Prepare for the impact that industry consolidation will have on provider decision-making. Focus on building relationships with system-level clinical leadership that will influence decisions regarding clinical pathways, formularies, and drug and device purchasing.
- **Medtech:** Connect your products to customer goals of enhancing access, capacity, and care timeliness.

03 Non-traditional investors and stakeholders disrupt the oncology ecosystem.

- **All life sciences:** Take advantage of the shifting environment by engaging with new market entrants.
- **Medtech:** Partner with solutions providers to integrate technology into broader care ecosystems, ensuring interoperability and data-sharing across platforms for seamless patient experiences.

Related content

Advisory Board resources



READY-TO-USE SLIDES

4 major trends shaping today's oncology market

[Read now](#)



MARKET INSIGHTS

4 predictions for cancer care in 2030

[Read now](#)



EXPERT INSIGHT

Oncology growth forecast: What you need to know

[Read now](#)



EXPERT INSIGHT

Q&A: Dan Nardi, CEO of Reimagine Care, on the future of at-home cancer care

[Read now](#)

Endnotes

1. Simpson KD and Fletcher S. [The State of Access and the Healthcare Experience for Patients with Cancer](#). ACCC. November 1, 2023.

Project Directors

Julia Elder

elderj@advisory.com

Lindsey Paul

lpaul14@advisory.com

Executive Leadership

Kaci Plattenburg

Nicholas Hula

LEGAL CAVEAT

Advisory Board has made efforts to verify the accuracy of the information it provides to members. This report relies on data obtained from many sources, however, and Advisory Board cannot guarantee the accuracy of the information provided or any analysis based thereon. In addition, Advisory Board is not in the business of giving legal, medical, accounting, or other professional advice, and its reports should not be construed as professional advice. In particular, members should not rely on any legal commentary in this report as a basis for action, or assume that any tactics described herein would be permitted by applicable law or appropriate for a given member's situation. Members are advised to consult with appropriate professionals concerning legal, medical, tax, or accounting issues, before implementing any of these tactics. Neither Advisory Board nor its officers, directors, trustees, employees, and agents shall be liable for any claims, liabilities, or expenses relating to (a) any errors or omissions in this report, whether caused by Advisory Board or any of its employees or agents, or sources or other third parties, (b) any recommendation or graded ranking by Advisory Board, or (c) failure of member and its employees and agents to abide by the terms set forth herein.

Advisory Board and the "A" logo are registered trademarks of The Advisory Board Company in the United States and other countries. Members are not permitted to use these trademarks, or any other trademark, product name, service name, trade name, and logo of Advisory Board without prior written consent of Advisory Board. All other trademarks, product names, service names, trade names, and logos used within these pages are the property of their respective holders. Use of other company trademarks, product names, service names, trade names, and logos or images of the same does not necessarily constitute (a) an endorsement by such company of Advisory Board and its products and services, or (b) an endorsement of the company or its products or services by Advisory Board. Advisory Board is not affiliated with any such company.

IMPORTANT: Please read the following.

Advisory Board has prepared this report for the exclusive use of its members. Each member acknowledges and agrees that this report and the information contained herein (collectively, the "Report") are confidential and proprietary to Advisory Board. By accepting delivery of this Report, each member agrees to abide by the terms as stated herein, including the following:

1. Advisory Board owns all right, title, and interest in and to this Report. Except as stated herein, no right, license, permission, or interest of any kind in this Report is intended to be given, transferred to, or acquired by a member. Each member is authorized to use this Report only to the extent expressly authorized herein.
2. Each member shall not sell, license, republish, or post online or otherwise this Report, in part or in whole. Each member shall not disseminate or permit the use of, and shall take reasonable precautions to prevent such dissemination or use of, this Report by (a) any of its employees and agents (except as stated below), or (b) any third party.
3. Each member may make this Report available solely to those of its employees and agents who (a) are registered for the workshop or membership program of which this Report is a part, (b) require access to this Report in order to learn from the information described herein, and (c) agree not to disclose this Report to other employees or agents or any third party. Each member shall use, and shall ensure that its employees and agents use, this Report for its internal use only. Each member may make a limited number of copies, solely as adequate for use by its employees and agents in accordance with the terms herein.
4. Each member shall not remove from this Report any confidential markings, copyright notices, and/or other similar indicia herein.
5. Each member is responsible for any breach of its obligations as stated herein by any of its employees or agents.
6. If a member is unwilling to abide by any of the foregoing obligations, then such member shall promptly return this Report and all copies thereof to Advisory Board.



655 New York Avenue NW, Washington DC 20001
202-266-5600 | advisory.com